Insight

Sep 11, 2024, 07:24

A roadmap for designing better immunotherapies – Cancer Research Institute

Cancer Research Institute (CRI) made the following post on LinkedIn:

“New findings from researchers, including 2022 William B. Coley Award recipient Dr. Judy Lieberman of Boston Children’s Hospital, indicate that tumors edit multiple genes to avoid recognition by the immune system. Published in Springer Nature Group’s Nature Immunology, the study additionally demonstrates a way to override these edits, by curbing tumor growth in a human-like mouse model of breast cancer, ‘which is notoriously resistant to immunotherapy.’ Discover how this study could provide a roadmap for designing better immunotherapies.”

Read further.
Source: Cancer Research Institute (CRI)/LinkedIn

Boston Children’s Hospital Breast Cancer cancer Cancer research Cancer Research Institute CRI Gene Editing immune system immunotherapy Judy Lieberman Nature Immunology OncoDaily Oncology Springer Nature Group

Dr. Richard Pazdur's 25 Year WAR on Cancer at the FDA!

China Anti-Cancer Association (CACA) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

Donald Trump: Thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of HHS

Overview of ASCO Breakthrough

Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More

Special Coverage